HOME >> BIOLOGY >> NEWS
Dana-Farber launches NFCR Center for Therapeutic Antibody Research and Engineering

BOSTONThe Dana-Farber Cancer Institute and the National Foundation for Cancer Research (NFCR) announced today the establishment of the NFCR Center for Therapeutic Antibody Engineering at Dana-Farber to assist scientists in developing new antibodies for cancer research. The new center, directed by Wayne Marasco, MD, PhD, of Dana-Farber, brings some of the most advanced research on antibody engineering together with the development of new therapies to combat cancer, the world's second leading cause of death.

With eight other NFCR research centers at universities and research hospitals worldwide, the NFCR Center at Dana-Farber will conduct therapeutic antibody research and provide high affinity human single-chain antibodies (sFv) to facilitate the ongoing cancer research of NFCR scientists. Many of the most promising anti-cancer drugs developed in recent years utilize humanized or human monoclonal antibodies Rituximab (anti-CD20); Herceptin (anti-Her2); Campath-H (anti-CD52). Other NFCR Centers have been established at Oxford, Yale, Penn State, University of California-Berkeley, University of Arizona, Freie Universitt Berlin, and the Institute of Medicinal Biotechnology in Beijing.

"This new initiative allows one of the world's strongest research programs at Dana-Farber to be networked into a collaborative partnership with NFCR scientists internationally. This collaborative effort adds a new dimension to NFCR's 'Laboratory Without Walls'," said Dr. Michael Wang, Director of Research at the National Foundation for Cancer Research in Bethesda, Maryland. "With this new NFCR Center for Therapeutic Antibody Engineering at Dana-Farber, we hope to create great synergies and multiple possibilities toward our goal of curing cancer."

How the Center Works

Traditionally, monoclonal antibodies have been derived from mouse models. However, this technique can produce Human Anti-mouse Antibody Responses (HAMA) when used clinically for human thera
'"/>

Contact: Bill Schaller
william_schaller@dfci.harvard.edu
617-632-5357
Dana-Farber Cancer Institute
13-Mar-2003


Page: 1 2 3

Related biology news :

1. Kinase backgrounder: Iressa discovery part of major kinase project at Dana-Farber
2. Dana-Farber launches Center for Applied Cancer Science
3. Dana-Farber scientists discover natural blocker of HIV-1 virus
4. Dana-Farber researchers to lead collaborative smallpox studies
5. NHGRI launches Centers for Excellence in Ethical, Legal, and Social Implications Research
6. Joslin Diabetes Center launches research section on developmental and stem cell biology
7. NIH launches first center in Nationwide Chemical Genomics Network
8. Biogeosciences.org launches
9. Clemson launches S.C. DNA Learning Center
10. STN International launches Derwent World Patents Index First View
11. JGI launches community sequencing program

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/9/2019)... ... May 09, 2019 , ... Akadeum Life Sciences today announced ... its microbubble technology. Unlike magnetic-based products, microbubbles use buoyancy to gently separate cells ... who participated in an early access program has been very encouraging and has ...
(Date:5/8/2019)... ... May 08, 2019 , ... ... diameter of 200 microns and a lead-in fiber of 100 microns. With dimensions ... standard and positioning itself as the world leader in the development of fiber ...
(Date:5/2/2019)... (PRWEB) , ... May 01, 2019 , ... ... that give families insight into their future children, announces a new publication titled, ... in the journal of Pregnancy and Child Health. Previous studies had only shown ...
Breaking Biology News(10 mins):
(Date:4/25/2019)... ... April 24, 2019 , ... Inference Solutions ... service organizations, today announced global availability of Inference Studio’s latest version, which makes ... sizes to harness the power of Google’s Contact Center AI (CCAI). ...
(Date:4/15/2019)... ... April 15, 2019 , ... Sirrus, Inc., ... $2 million bench plant expansion to increase production of methylene malonate monomers and ... and construction of Sirrus’ full-scale production facility, which is scheduled to break ground ...
(Date:4/9/2019)... ... April 09, 2019 , ... USDM ... capacity of life sciences organizations to accelerate innovation and maximize productivity, announces that ... the past 12 months. , USDM’s Cloud Assurance is a managed ...
(Date:4/8/2019)... SAN FRANCISCO (PRWEB) , ... April 08, 2019 , ... ... to accredited investors a $15 million preferred equity investment in the privately held pharmaceutical ... dysfunction. Its leading drug, Lorexys, is targeted at female hypoactive sexual dysfunction disorder and ...
Breaking Biology Technology:
Cached News: